Chongqing Kingbear

Chongqing Kingbear Pharmaceutical is a China-based biotechnology company dedicated to the research, development, and industrialization of recombinant protein and peptide therapeutics. The company primarily focuses on metabolic and endocrine disorders, with a robust pipeline featuring insulin analogs and GLP-1 receptor agonists for the treatment of diabetes and obesity. Kingbear maintains large-scale GMP manufacturing capabilities in Chongqing, enabling the production of high-purity biologics through advanced fermentation and purification technologies. Their business model encompasses the full value chain from early-stage R&D to commercial-scale manufacturing, aiming to provide affordable biopharmaceutical solutions for the global market. The company's lead programs include biosimilar versions of insulin glargine and liraglutide which are in late-stage clinical development.